The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Allogeneic endothelial cell therapy for lymphoma patients undergoing auto-HSCT
Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses a Phase I trial (NCT03925935) of allogeneic engineered endothelial cell therapy for lymphoma patients undergoing high-dose conditioning regimens and autologous hematopoietic cell transplantation (auto-HSCT). AB-205 is a first-in-human engineered cell-therapy of umbilical vein endothelial cells. As high-dose therapy is associated with severe regimen-related toxicities (SRRT), AB-205, shown to accelerate the recovery of vascular niches, is intended to reduce these toxicities. The initial results show that AB-205 appears to be safe and potentially effective, with few adverse events and reduced SRRT occurrence. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Amgen, Janssen, Celgene, Quintiles, Pfizer, CSL Behring, Sanof, Adienne, Kite, JAZZ, Actinuum
